AnaCardio

Stockholm clinical-stage biopharma developing AC01, a ghrelin-pathway inotropic agent for heart failure with reduced ejection fraction.

View on the globe

$90MEquity raised in 2025–20262025 $19M · 2026 $71M · 2 equity rounds
$90MEquity raised, all time2 equity rounds sourced so far
—Latest valuationnot disclosed

Rounds over time log-scaled amounts

Funding history: 2 rounds from 9 Jan 2025 to 30 Sep 2026, $90M equity disclosed. Earlier rounds exist but are not sourced.9 Jan 2025: Series A extension, $19M; 30 Sep 2026: Series B, $71M$1M$3M$10M$30M$100MEarlier rounds exist but are not sourced yet← earlier rounds not sourced20252026Equity round30 Sep 2026 · Series B · $71M · led by Novo Holdings, Ljungström9 Jan 2025 · Series A extension · $19M · led by Novo Holdings, Pureos Bioventures, Sound BioventuresSeries B · $71MSeries A · $19M
Funding history: 2 rounds from 9 Jan 2025 to 30 Sep 2026, $90M equity disclosed. Earlier rounds exist but are not sourced.9 Jan 2025: Series A extension, $19M; 30 Sep 2026: Series B, $71M$1M$3M$10M$30M$100MEarlier rounds exist but are not sourced yetearlier rounds not sourced2026Equity round30 Sep 2026 · Series B · $71M · led by Novo Holdings, Ljungström9 Jan 2025 · Series A extension · $19M · led by Novo Holdings, Pureos Bioventures, Sound Bioventures$71M$19M

Funding history 2 rounds · 2 sources · newest first

Earlier rounds not yet sourced. AnaCardio raised before 9 Jan 2025; only the rounds below are sourced so far, so its all-time equity total understates its history.

  1. Series B
    Amount$71MEUR 62.5M
    Post-money—
    ✓ Confirmed
    Lead
    Novo Holdings, Ljungström
    Also
    Helsinn, Pureos Bioventures, Sound Bioventures, Industrifonden, Flerie, LLD Nybohov Invest AB, Innovestor Life Science
    Note
    Release gives EUR 62.5M only. USD converted at the ECB reference rate of 1.1355 USD per EUR on 2026-09-30 (announcement date), so approximate. Co-led by Novo Holdings and the Ljungstrom family office. Valuation not stated (pre- or post-money not stated). Company says it has raised around EUR 100M to date.
    Sources
  2. Series A extension
    Amount$19MSEK 205M
    Post-money—
    ✓ Confirmed
    Lead
    Novo Holdings, Pureos Bioventures, Sound Bioventures
    Also
    Flerie, Industrifonden, Fredrik Ljungström, Ann-Helene Ljungström
    Note
    Company release gives USD 19M (SEK 205M); the release itself states the amount in USD and SEK, so the USD figure is as stated. Novo Holdings, Pureos and Sound Bioventures co-led. Valuation not stated. Company newsroom lists it as an extension of the Series A (the SEK 50M second tranche completing an earlier Series A is not dated).
    Sources
  3. Earlier rounds not yet sourced

Investors 11

  • Novo Holdings2
  • Pureos Bioventures2
  • Sound Bioventures2
  • Ljungström1
  • Flerie2
  • Industrifonden2
  • Ann-Helene Ljungström
  • Fredrik Ljungström
  • Helsinn
  • Innovestor Life Science
  • LLD Nybohov Invest AB

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Related companies shared investors

Also in the Stockholm hub see on the globe

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. AnaCardio and its logo are trademarks of their owners, used here for identification only.